Favorable research results from the PURPOSE 1 trial (South Africa and Uganda) have been published in the New England Journal of Medicine and presented at IAS 2024 in Munich, use of the twice-yearly injectable lenacapavir (Gilead) has demonstrated 100% efficacy for HIV prevention in women. Results from PURPOSE 2, which is assessing efficacy of lenacapavir in other populations and countries, is underway. This advance has remarkable potential to accelerate HIV prevention at a scale that has not yet been seen.
To access the IAS Press release: https://www.iasociety.org/news-release/statement-ias-president-sharon-lewin-full-results-purpose-1-trial-twice-yearly
To read the published article in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2407001